المصدر: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: National Cancer Institute (NCI), Leidos, UNICO Foundation

المصدر: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

المؤلفون: Agenus Inc., Lustgarten Foundation, Oncovir, Inc.

المصدر: A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma

المؤلفون: Natera, Inc.

المصدر: Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

المؤلفون: AstraZeneca, Private Philanthropic Funds

المصدر: A Pilot Study of Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers

المؤلفون: Connor's Cure, National Cancer Institute (NCI)

المساهمون: James Felker, Assistant Professor

المصدر: A Phase II Study of Vaccinations with HLA-A2 Restricted Glioma Antigen Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)

المصدر: A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer

المؤلفون: National Institutes of Health (NIH)

المصدر: A Phase I Study of in Situ Immunomodulation with CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients with Unresectable and Metastatic Solid Tumors with Injectable Palpable Disease

المصدر: A Pilot Study to Evaluate the Safety and Feasibility of Neoantigen-Targeted Dendritic Cell Vaccination in Diffuse Hemispheric Glioma, H3 G34-Mutant

المؤلفون: Ellie Kavalieros Fund, Translational Brain Tumor Research Fund, Connor's Cure

المساهمون: James Felker, Assistant Professor

المصدر: A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1;32(19):2050-8. doi: 10.1200/JCO.2013.54.0526. Epub 2014 Jun 2.
Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol. 2014 Aug;119(1):7-15. doi: 10.1007/s11060-014-1448-8. Epub 2014 May 3.

المؤلفون: The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH)

المساهمون: David Reardon, MD, Prinicipal Investigator

المصدر: A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

المصدر: Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas

المؤلفون: University of Minnesota

المساهمون: Jennie Taylor, Principal Investigator

المصدر: Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma
Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 Feb 1;132(3):e151239. doi: 10.1172/JCI151239.

المؤلفون: Agenus Inc., Private Philanthropic Funds, National Institutes of Health (NIH)

المصدر: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma

المساهمون: Patrick Ott, MD, PhD, Principal Investigator

المصدر: A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma
Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021 Jul 26;13(1):120. doi: 10.1186/s13073-021-00940-9.
Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 Mar;27(3):515-525. doi: 10.1038/s41591-020-01206-4. Epub 2021 Jan 21.

المصدر: A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV

المساهمون: Ashutosh Kumar Tewari, Professor and System Chair, Milton and Carroll Petrie Department of UrologyDirector of Center of Excellence for Prostate Cancer at the Tisch Cancer Institute

المصدر: Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting

المؤلفون: National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.

المصدر: Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab with Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients with Surgically Accessible Recurrent/Progressive Glioblastoma

المساهمون: Olivera Finn, Professor of Immunology

المصدر: Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (polyinosinic-polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose) or HILTONOL™ Adjuvant Vaccine in Patients with Localized and Locally Advanced Non-Small Cell Lung Cancer

المصدر: A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer